<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03500445</url>
  </required_header>
  <id_info>
    <org_study_id>IRB17-1097</org_study_id>
    <nct_id>NCT03500445</nct_id>
  </id_info>
  <brief_title>Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma</brief_title>
  <official_title>Open-label, Single-arm, Phase 2 Study of Initial Treatment With Daratumumab (Darzalex), Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine response rate after 8 cycles of D-KRd (daratumumab,&#xD;
      carfilzomib, lenalidomide (Revlimid) and dexamethasone in patients with multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 13, 2019</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of stringent complete response (sCR)</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of minimal residual disease (MRD)-negative disease as assessed by Next Generation Sequencing</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long term rate of MRD-negative disease</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of progression free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of grade 2 or higher side effects as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 criteria</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Myeloma</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Treatment Arm (D-KRd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Daratumumab (16 mg/kg) will be administered as an IV infusion:&#xD;
Cycle 1-2: 16 mg/kg weekly&#xD;
Cycles 3-8: 16 mg/kg IV infusion every 2 weeks&#xD;
Cycles 9-24: 16 mg/kg IV infusion Day 1</description>
    <arm_group_label>Treatment Arm (D-KRd)</arm_group_label>
    <other_name>DARZALEX®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Carfilzomib will be given as an IV infusion over 30 minutes:&#xD;
Cycle 1: 20 mg/m2 Days 1, 2; 36 mg/m2 Days 8, 9, 15, 16. Alternatively, intermediate dose escalation (to 27mg/m2 on days 8, 9 of cycle 1) will be allowed at the treating physician's discretion.&#xD;
Cycle 2-9: 36 mg/m2 (or best tolerated dose) Days 1, 2, 8, 9, 15 and 16&#xD;
Cycles 9-24: 36 mg/m2 (or best tolerated dose) Days 1, 2, 15 and 16</description>
    <arm_group_label>Treatment Arm (D-KRd)</arm_group_label>
    <other_name>KYPROLIS®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Lenalidomide will be taken orally as follows:&#xD;
• Cycles 1-24: 25 mg (or best tolerated dose) PO Days 1-21</description>
    <arm_group_label>Treatment Arm (D-KRd)</arm_group_label>
    <other_name>REVLIMID®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone will be administered prior to carfilzomib (on days that they coincide), as follows:&#xD;
Cycles 1-9: 40 mg PO (subjects ≤ 75 years) or 20 mg PO (subjects ≥ 75 years) per week&#xD;
Cycles 9-24: 20 mg PO per week&#xD;
During weeks when daratumumab is given: 40 mg dexamethasone weekly, 20 mg prior to daratumumab infusion and 20 mg PO the day after&#xD;
During weeks with no daratumumab, single dose of 20 mg on day 1</description>
    <arm_group_label>Treatment Arm (D-KRd)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed, previously untreated myeloma requiring systemic chemotherapy&#xD;
&#xD;
             • Prior treatment of hypercalcemia or spinal cord compression or active and/or&#xD;
             aggressively progressing myeloma with corticosteroids or lenalidomide or&#xD;
             bortezomib-based regimens does not disqualify the patient (the treatment dose should&#xD;
             not exceed the equivalent of 160 mg of dexamethasone in a 4 week period or not more&#xD;
             than 1 cycle of Proteasome Inhibitor / Immunomodulatory-based therapy)&#xD;
&#xD;
          -  Both transplant and non-transplant candidates are eligible.&#xD;
&#xD;
          -  Diagnosis of symptomatic multiple myeloma as per current International Myeloma Working&#xD;
             Group (IMWG) uniform criteria prior to initial treatment&#xD;
&#xD;
          -  Monoclonal plasma cells in the Bone Marrow (BM) ≥ 10% or presence of a biopsy-proven&#xD;
             plasmacytoma&#xD;
&#xD;
          -  Measurable disease, prior to initial treatment as indicated by one or more of the&#xD;
             following:&#xD;
&#xD;
               -  Serum M-protein ≥ 1 g/dL&#xD;
&#xD;
               -  Urine M-protein ≥ 200 mg/24 hours&#xD;
&#xD;
               -  If serum protein electrophoresis is felt to be unreliable for routine M-protein&#xD;
                  measurement, then quantitative immunoglobulin levels are acceptable&#xD;
&#xD;
               -  Serum freelite measurable disease as per current IMWG criteria&#xD;
&#xD;
          -  Bone marrow specimen will be required at study entry; available DNA sample from&#xD;
             pre-induction BM will be used for calibration step for MRD evaluation by gene&#xD;
             sequencing.&#xD;
&#xD;
          -  Males and females ≥ 18 years of age&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1&#xD;
&#xD;
          -  Adequate hepatic function, with bilirubin ≤ 1.5 x upper limit of normal (ULN) and&#xD;
             aspirate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN&#xD;
&#xD;
          -  Absolute Neutrophil Count (ANC) ≥ 1.0 x 109/L, hemoglobin ≥ 8 g/dL, platelet count ≥&#xD;
             75 x 109/L.&#xD;
&#xD;
          -  Calculated creatinine clearance (by Cockroft-Gault) ≥ 50 mL/min or serum creatinine&#xD;
             below 2 g/dL&#xD;
&#xD;
          -  Woman of childbearing potential must have 2 negative pregnancy tests prior to&#xD;
             initiating lenalidomide.&#xD;
&#xD;
          -  Woman of childbearing potential must agree to use 2 reliable forms of contraception&#xD;
             simultaneously or to practice complete abstinence from heterosexual intercourse during&#xD;
             the following time periods related to this study: 1) for at least 28 days before&#xD;
             starting lenalidomide; 2) while participating in the study; and 3) for at least 30&#xD;
             days after discontinuation from the study.&#xD;
&#xD;
          -  Male subjects must agree to use a latex condom during sexual contact with females of&#xD;
             childbearing potential while participating in the study and for at least 90 days&#xD;
             following discontinuation from the study even if he has undergone a successful&#xD;
             vasectomy.&#xD;
&#xD;
          -  All study participants in the US must be consented to and registered into the&#xD;
             mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS®) program and be&#xD;
             willing and able to comply with the requirements of Revlimid REMS®.&#xD;
&#xD;
          -  Voluntary written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Frail non-transplant candidates, defined as in Palumbo et al, Blood 2015.&#xD;
&#xD;
          -  Non-secretory or hyposecretory multiple myeloma, prior to initial treatment defined as&#xD;
             &lt;1.0 g/dL M-protein in serum, &lt;200 mg/24 hr urine M-protein, and no measurable disease&#xD;
             as per IMWG by Freelite.&#xD;
&#xD;
          -  POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and&#xD;
             skin changes)&#xD;
&#xD;
          -  Amyloidosis&#xD;
&#xD;
          -  Plasma cell leukemia&#xD;
&#xD;
          -  Waldenström's macroglobulinemia or Immunoglobulin M-producing (IgM) myeloma&#xD;
&#xD;
          -  Radiotherapy to multiple sites or immunotherapy within 4 weeks before start of&#xD;
             protocol treatment (localized radiotherapy to a single site at least 1 week before&#xD;
             start is permissible)&#xD;
&#xD;
          -  Participation in an investigational therapeutic study within 3 weeks or within 5 drug&#xD;
             half-lives (t1/2) prior to first dose, whichever time is greater&#xD;
&#xD;
          -  Potential subjects with evidence of progressive disease as per IMWG criteria&#xD;
&#xD;
          -  Patients not able to tolerate daratumumab, carfilzomib, lenalidomide or dexamethasone&#xD;
&#xD;
          -  Peripheral neuropathy ≥ Grade 2 at screening&#xD;
&#xD;
          -  Diarrhea &gt; Grade 1 in the absence of antidiarrheals&#xD;
&#xD;
          -  Central Nervous System (CNS) involvement&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Major surgery within 3 weeks prior to first dose.&#xD;
&#xD;
          -  Myocardial infarction within 6 months prior to enrollment, New York Heart Association&#xD;
             (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled&#xD;
             ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active&#xD;
             conduction system abnormalities&#xD;
&#xD;
          -  Prior or concurrent pulmonary embolism&#xD;
&#xD;
          -  Known moderate or severe persistent asthma or known chronic obstructive pulmonary&#xD;
             disease (COPD)&#xD;
&#xD;
               -  Known or suspected chronic obstructive pulmonary disease (COPD) with a forced&#xD;
                  expiratory volume in 1 second (FEV1) &lt;50% of predicted normal&#xD;
&#xD;
               -  Moderate or severe persistent asthma within the past 2 years, or currently has&#xD;
                  uncontrolled asthma of any classification. Note that subjects who currently have&#xD;
                  controlled intermittent asthma or controlled mild persistent asthma are allowed&#xD;
                  in the study.&#xD;
&#xD;
          -  Rate-corrected QT interval of electrocardiograph (QTc) &gt; 470 msec on a 12-lead ECG&#xD;
             during screening&#xD;
&#xD;
          -  Uncontrolled hypertension or diabetes&#xD;
&#xD;
          -  Acute infection requiring systemic antibiotics, antivirals, or antifungals within two&#xD;
             weeks prior to first dose&#xD;
&#xD;
          -  Known seropositive for or active viral infection with human immunodeficiency virus&#xD;
             (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are&#xD;
             seropositive because of hepatitis B virus vaccine are eligible.&#xD;
&#xD;
          -  Non-hematologic malignancy or non-myeloma hematologic malignancy within the past 3&#xD;
             years except a) adequately treated basal cell, squamous cell skin cancer, thyroid&#xD;
             cancer, carcinoma in situ of the cervix, or prostate cancer &lt; Gleason Grade 6 with&#xD;
             stable prostate specific antigen levels or cancer considered cured by surgical&#xD;
             resection alone&#xD;
&#xD;
          -  Any clinically significant medical disease or condition that, in the Investigator's&#xD;
             opinion, may interfere with protocol adherence or a subject's ability to give informed&#xD;
             consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrzej Jakubowiak, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda McIver</last_name>
      <phone>773-834-5884</phone>
      <email>amciver@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Andrzej Jakubowiak, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 9, 2018</study_first_submitted>
  <study_first_submitted_qc>April 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2018</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

